INFECTION RATES AND IMPACT OF G-CSF PROPHYLAXIS IN CLL PATIENTS RECEIVING FRONTLINE VENETOCLAX-OBINUTUZUMAB: A REAL-WORLD STUDY BY THE CLL CAMPANIA GROUP (SIE 2026) - Oct 6, 2026 - Abstract #DP140; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "Notably, an intensive G-CSF prophylactic strategy did not significantly reduce infection rates or treatment modifi- cations. An extended follow up and a larger cohort are re- quired to confirm these findings."
Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Richter's Syndrome
|
|
M. Lucignano1; A. Fresa2; C. Giordano3; R. Reina4; B. Pocali5; D. Abagnale6; F. Graziani7; L. Mettivier8; M. R. Villa9; V. Amico10; A. Pareto11; S. Basile11; A. Sica12; M. G. Ferrara7; M. Esposito2; V. Sammartano3; F. Trastulli5; G. D'Arena13; G. R. Nunziata7; G. Farina6
|